SUBSCRIBE
SUBSCRIBE
Bio NC

Salix Pharmaceuticals, Ltd. Reports Digestive Disease Week 2006 UPDATE

May 24, 2006 | 
1 min read
RALEIGH, N.C.--(BUSINESS WIRE)--May 24, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today announced results of one investigator-initiated trial of XIFAXAN® (rifaximin) tablets 200 mg presented today at Digestive Disease Week® 2006.
Events
MORE ON THIS TOPIC
Creative background as a blue abstract extreme perspective design element representing time travel or Psychedelic and hallucinogenic consciousness trip as a 3D illustration.
Psychedelics
Psychedelic therapies ride wave of public favor into FDA hearing
September 14, 2026
 · 
3 min read
 · 
Michael Gibney
Creative concept of leadership and innovation with a glowing blue light bulb leading paper planes. Symbol of advanced technology, AI-driven strategy, and visionary direction in a digital future.
FDA
Biotech leaders call for streamlining of INDs as FDA’s TrialBlazer rolls out
August 3, 2026
 · 
9 min read
 · 
Jef Akst
chain which breaks under pressure with the back wall
Diabetes
Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
July 20, 2026
 · 
7 min read
 · 
Michael Gibney
Window cleaner using a squeegee to wash a window
Alzheimer’s disease
AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug
July 15, 2026
 · 
6 min read
 · 
Heather McKenzie